Biolife Solutions Inc: CEO De Greef Roderick sold 1,191,326 shares

What happened

• De Greef Roderick, CEO, reported multiple transactions on Oct 6, 2026: two grants (225,670 and 237,460 shares) were acquired as awards, 364,872 shares were disposed at $38.61 for $14,087,708, and 826,454 shares were disposed to the issuer.
• The filing ties the dispositions and vesting to the consummation of a merger effective Oct 6, 2026; the filing states each outstanding share was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock.

Key details

• Transaction dates and prices: Oct 6, 2026; 364,872 shares disposed at $38.61 per share for $14,087,708; other dispositions show no per-share price in the filing (merger consideration described in footnote).
• Shares owned after the transactions: not reported in the Form 4 excerpt provided.
• Awards and vesting: the two restricted stock grants were made under the 2023 omnibus plan and, per the filing, vested immediately prior to the merger as to approximately 200% of the number granted based on total shareholder return tests covering Jan 1, 2025–Oct 2, 2026 and Jan 1, 2026–Oct 2, 2026.
• Tax withholding: 364,872 shares reflect shares withheld/disposed to cover tax withholding obligations in connection with the vesting of market-based restricted stock.
• Merger consideration: at the effective time of the first merger each share was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement.
• Filing timeliness: the Form 4 was filed on Oct 8, 2026 for transactions on Oct 6, 2026 (filed within two business days; no late filing indicated).

Why it may matter

• The filing shows shares were acquired as restricted stock awards and then vested and were used/converted in connection with the merger; some shares were withheld or disposed to cover tax liabilities.
• The filing reports dispositions to the issuer under the merger agreement and a cash value for a portion of the shares sold.
• This filing does not show why the insider traded or why the company acted.